Sage Therapeutics (SAGE) announced that Dr. Laura Gault, Chief Medical Officer, has decided to pursue a new opportunity and will depart the Company, effective March 21, 2025. Dr. Gault joined Sage Therapeutics in November 2022 and has led the Company’s product pipeline through all stages of development. Mike Quirk, Chief Scientific Officer, will assume key responsibilities, including strategic guidance for clinical development programs, on an interim basis.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SAGE:
- SAGE Therapeutics: Hold Rating Amid Gradual Growth Prospects and Market Challenges
- Sage Therapeutics price target established at JPMorgan
- SAGE Therapeutics Faces Legal Challenges: Potential Impact on Financial Stability and Growth
- Hold Rating for SAGE Therapeutics: Inventory Challenges and Strategic Prospects
- SAGE Therapeutics’ Earnings Call: ZURZUVAE’s Success Amid Challenges